Wuhan Historical Income Statement

300871 Stock   11.40  0.01  0.09%   
Historical analysis of Wuhan Hvsen income statement accounts such as Other Operating Expenses of 5.6 M, Net Income Applicable To Common Shares of 96.4 M or Income Tax Expense of 4.4 M can show how well Wuhan Hvsen Biotechnology performed in making a profits. Evaluating Wuhan Hvsen income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Wuhan Hvsen's future profits or losses.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Wuhan Hvsen Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Wuhan Hvsen Biotechnology is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Wuhan Hvsen Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Wuhan Income Statement Analysis

Wuhan Hvsen Biotechnology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Wuhan Hvsen shareholders. The income statement also shows Wuhan investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Wuhan Hvsen Income Statement Chart

At present, Wuhan Hvsen's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Net Income Applicable To Common Shares is expected to grow to about 96.4 M, whereas Other Operating Expenses is forecasted to decline to about 5.6 M.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Wuhan Hvsen Biotechnology. It is also known as Wuhan Hvsen overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Revenue

Total revenue comprises all receipts Wuhan Hvsen Biotechnology generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Wuhan Hvsen Biotechnology minus its cost of goods sold. It is profit before Wuhan Hvsen operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.
Most accounts from Wuhan Hvsen's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Wuhan Hvsen Biotechnology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Wuhan Hvsen Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
At present, Wuhan Hvsen's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Net Income Applicable To Common Shares is expected to grow to about 96.4 M, whereas Other Operating Expenses is forecasted to decline to about 5.6 M.
 2023 2024 (projected)
Minority Interest17.0K14.4K
Income Tax Expense4.6M4.4M

Wuhan Hvsen income statement Correlations

-0.260.81-0.7-0.770.490.560.810.22-0.53-0.56-0.410.780.410.850.850.77-0.59-0.56
-0.260.160.750.630.430.230.040.570.880.850.80.00.51-0.03-0.05-0.420.840.85
0.810.16-0.47-0.550.590.390.710.29-0.24-0.3-0.130.720.50.730.730.59-0.33-0.3
-0.70.75-0.470.97-0.06-0.13-0.440.190.870.960.63-0.480.03-0.51-0.52-0.860.980.96
-0.770.63-0.550.97-0.2-0.3-0.560.010.760.910.49-0.56-0.16-0.61-0.62-0.940.920.91
0.490.430.59-0.06-0.20.830.890.880.310.20.470.870.940.850.840.470.150.2
0.560.230.39-0.13-0.30.830.840.860.180.060.410.770.90.790.80.560.030.06
0.810.040.71-0.44-0.560.890.840.67-0.12-0.210.060.980.81.00.990.73-0.25-0.21
0.220.570.290.190.010.880.860.670.590.390.760.60.950.60.590.310.360.39
-0.530.88-0.240.870.760.310.18-0.120.590.930.88-0.180.41-0.21-0.22-0.550.920.93
-0.560.85-0.30.960.910.20.06-0.210.390.930.72-0.240.25-0.28-0.29-0.741.01.0
-0.410.8-0.130.630.490.470.410.060.760.880.720.030.63-0.03-0.04-0.20.710.72
0.780.00.72-0.48-0.560.870.770.980.6-0.18-0.240.030.750.980.980.73-0.28-0.24
0.410.510.50.03-0.160.940.90.80.950.410.250.630.750.740.740.460.210.25
0.85-0.030.73-0.51-0.610.850.791.00.6-0.21-0.28-0.030.980.741.00.75-0.32-0.28
0.85-0.050.73-0.52-0.620.840.80.990.59-0.22-0.29-0.040.980.741.00.76-0.34-0.29
0.77-0.420.59-0.86-0.940.470.560.730.31-0.55-0.74-0.20.730.460.750.76-0.77-0.74
-0.590.84-0.330.980.920.150.03-0.250.360.921.00.71-0.280.21-0.32-0.34-0.771.0
-0.560.85-0.30.960.910.20.06-0.210.390.931.00.72-0.240.25-0.28-0.29-0.741.0
Click cells to compare fundamentals

Wuhan Hvsen Account Relationship Matchups

Wuhan Hvsen income statement Accounts

201920202021202220232024 (projected)
Interest Expense5.2M2.3M2.9M18.4M28.2M29.6M
Other Operating Expenses3.9M4.4M4.9M8.8M10.2M5.6M
Net Income Applicable To Common Shares68.8M150.2M132.9M52.7M60.6M96.4M
Income Tax Expense9.8M25.9M18.0M4.0M4.6M4.4M
Tax Provision9.8M25.9M18.0M4.0M(4.3M)(4.1M)
Net Interest Income(4.5M)3.9M4.4M(14.1M)(24.3M)(23.0M)
Interest Income2.0M6.5M7.7M4.8M4.3M4.4M
Selling General Administrative16.1M66.3M64.5M59.5M66.2M52.6M
Total Revenue427.2M777.5M996.2M1.0B1.0B796.0M
Gross Profit163.7M287.9M270.7M225.4M213.3M243.2M
Operating Income82.2M178.0M136.2M79.3M41.9M82.1M
Net Income From Continuing Ops68.8M150.2M132.9M52.7M16.8M15.9M
Ebit72.9M162.4M135.3M61.0M70.2M111.9M
Research Development21.1M28.4M46.9M40.1M44.6M34.5M
Ebitda100.4M197.4M182.2M137.7M158.3M152.5M
Cost Of Revenue263.5M489.6M725.5M797.5M806.5M552.8M
Total Operating Expenses343.9M599.4M860.0M943.6M977.8M682.8M
Reconciled Depreciation12.5M19.1M28.5M62.6M120.4M126.4M
Income Before Tax78.6M176.0M150.8M56.7M12.4M11.8M
Net Income68.8M150.2M132.9M52.7M16.8M15.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Wuhan Stock

Wuhan Hvsen Biotechnology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Wuhan Hvsen shareholders. The income statement also shows Wuhan investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).